INTRODUCTION
Obesity is an epidemic healthcare problem worldwide.
In the United States, the prevalence of obesity, defined as a body mass index (BMI) ≥ 30 kg/m 2 , has increased, and now includes ＞30% of the population [1] . Data 
METHODS

Data source and patient identification
We used a retrospective cohort design with a medical 
Data collection
Baseline height, weight, blood pressure, and laboratory data were collected by physical examination and laboratory assessments within a few days before bariatric surgery in the surgery group. These data were collected in the conventional therapy group at the first visit to start a weight loss program in the family medicine departments.
Weight, blood pressure, and laboratory findings were collected over time when the subjects visited the hospital.
Medical history information before bariatric surgery or the first visit for conventional therapy was investigated 
Clinical effectiveness
The clinical effectiveness of weight loss was investigated using two parameters. The first parameter was change in weight (%), calculated by dividing weight change from baseline by baseline weight. The second parameter was the percentage of excess weight loss (%EWL), calculated by dividing the weight change from baseline by excess weight, which was obtained by subtracting ideal body weight from actual baseline weight. Ideal body weight was calculated using height-adjusted weight, depending on sex, for a medium frame according to the 1983 Metropolitan Life Insurance Company tables [9] .
Recovery from comorbidities such as diabetes, hypertension, and dyslipidemia was investigated over time. 
Statistical analysis
We summarized the patient characteristics of the two groups, and compared the baseline characteristics between groups using a t-test for continuous variables and a chi-squared test for categorical variables. To investigate weight change, weight measurements obtained during routine visits were summarized at 3-month intervals. For example, if one patient's weight was measured twice during a 3-month period from baseline, the weight value at 3 months was the mean value of the two measurements.
Study outcomes such as change in weight (%) and %EWL were summarized at 0 (baseline), 3, 6, 9, 12, 15, and 18 months, and 95% confidence intervals (CIs) were calculated. The t-test was used to compare study outcomes between the two groups at each time point. Matching and the generalized estimating equation (GEE) model were used to balance confounding factors at baseline between the two groups [10] . Three matching variables were considered: age (±5 years), BMI (±3 kg/m 2 ), and sex. The dependent variable for the GEE model was change in weight (%), and measurement time, age, and sex were included as independent variables. Measurement time and age were inputted as continuous variables. Two independent researchers inputted data into the data collection forms. Then, data entry errors were checked using the SAS ver. 9.2 (SAS Institute Inc., Cary, NC, USA) and corrected. Data were analyzed using the SAS software.
RESULTS
Clinical characteristics
We identified 261 subjects in the surgery group and 224 subjects in the conventional therapy group. Patient characteristics are shown in Table 1 . The median follow-up periods were 9 months for the surgery group and 8 months for the conventional therapy group. BMI was higher in the surgery group than in the conventional therapy group (mean ± standard deviation, 39.0 ± 6.2 vs. 34.3 ± 3.8 kg/m 2 ).
thesurgery.or.kr Mean age was lower in the surgery group than in the conventional therapy group (36 ± 10.8 vs. 41 ± 13.3 years). In total, 75.5% of patients in the surgery group and 56.7% of patients in the conventional therapy group were female.
Diabetes was more prevalent in the surgery group than in the conventional therapy group (39.1% vs. 12.9%). In the surgery group, 27.6% of procedures were LAGB, 28.0%
were LRYGB, and 44.4% were LSG. Most subjects (95%) in the conventional group used antiobesity drugs. Phentermine (26.3%) was the most frequently prescribed medicine, followed by sibutramine (24.1%), fluoxetin (12.8%), mazindole (10.5%), bupropion (10.1%), and orilistat (4.9%).
Sibutramine was withdrawn from the Korean market at the end of 2010.
Change in body weight
Treatment outcomes such as change in weight (%) are shown in Fig. 1 (Fig. 2 ).
There was no significant difference of change in weight (%) from baseline to 18 months according to operative procedures (20.8% for LAGB, 26.6% for LRYGB, and 22.3% for LSG).
After age, sex, and BMI were matched between the two groups, the pattern of change in weight (%) was similar to that before matching. Weight change was greater in the surgery group, with a similar significance before and after matching (P ＜ 0.001).
Time and treatment effects for change in weight (%) from baseline using the GEE are described in Table 2 .
Change in weight (%) was 1.2% greater in the surgery Values are presented as number (%). 
Changes in comorbidities
Recovery from concomitant diseases such as diabetes, hypertension, and dyslipidemia was more frequent in the surgery group than in the conventional therapy group (Table 3) . While 57.1%, 47.1%, and 83.9% of subjects recovered from diabetes, hypertension, and dyslipidemia, respectively, in the surgery group, 9.5%, 19.8%, and 23.6% of subjects recovered from these comorbidities in the conventional group. (Table 4) .
Adverse events
DISCUSSION
In this retrospective study, we examined the records of patients who had undergone bariatric surgery to determine the effectiveness for weight reduction and improvement in comorbid diseases, as compared with that of conventional medical therapy. We showed that bariatric surgery was more effective than conventional therapy for weight loss and treatment of comorbid diseases in severely obese patients in Korea. Observed effects on weight loss were consistent after adjusting for major confounders such as BMI, age, and sex.
The effectiveness of bariatric surgery has been well established in Western countries, where the prevalence of obesity is high. Bariatric surgery is the most effective option for weight loss in severely obese patients [11] [12] [13] .
However, the first bariatric surgery was performed in Our weight loss findings are in agreement with those of retrospective studies [13, 14] . Many studies have reported not only the weight reduction effect, but also the survival effect of bariatric surgery [13, 14] . However, we could not demonstrate a favorable survival effect of bariatric surgery in Korean obese patients because the observation period was limited to 18 months after surgery. Nevertheless, the weight reduction pattern we observed was comparable to those reported in previous studies, including the early (18-month) results of the Swedish Obese Subjects (SOS) study [13] , a large-scale multicenter cohort study. In contrast, the control group in our study showed 8% weight loss after 18 months, whereas the control group in the SOS study showed only 1% weight change. The reasons for this discrepancy may be that the mean BMI of the control group was lower in the present study than in the SOS study, and that conventional medical therapy in the present study was actively conducted in tertiary hospitals.
Recovery from comorbidities such as diabetes, hypertension, and dyslipidemia was better in the surgery group than in the conventional therapy group in the present study. The remission of diabetes was observed in 57.1% of subjects in the surgery group and 9.5% of subjects in the conventional therapy group. This result was consistent with those of previous studies [15] [16] [17] .
Buchwald et al. [17] reported a large-scale meta-analysis of 22,094 patients. In that study, diabetes was completely resolved in 76.8% of patients. In two comparative cohort studies, the SOS study [13] and the Utah Obesity study [14] , diabetes remission rates were 66% and 74%, respectively, in the surgery groups, but ＜1% in the control groups.
Two prospective randomized trials assessing the results of surgical treatment of obese patients with diabetes have been published in the New England Journal of Medicine.
Schauer et al. [18] evaluated the efficacy of intensive medical therapy alone versus medical therapy plus LRYGB or LSG in 150 obese patients with uncontrolled type 2 diabetes. The target HbA1C concentration of 6.0% or less at 12 months was achieved in 12%, 42%, and 37% of patients in the medical therapy, LRYGB, and LSG groups, respectively. The remission rates, evaluated by achievement of the endpoint without the use of hypoglycemic agents, were 0%, 100%, and 37%, respectively. Mingrone et al. [19] assigned patients to undergo RYGB, biliopancreatic diversion, or standard medical therapy. After 2 years, complete remission rates of diabetes were 75% for patients who underwent RYGB and 95% for those who underwent biliopancreatic diversion, whereas no remission occurred in the medical therapy group. In contrast, diabetes remission was also observed in the conventional therapy group in the present study because these patients received intensive medical treatment at a tertiary medical center.
Obesity remains a major cause of illness and death, and bariatric surgery appears to be the only intervention that consistently results in substantial, sustained weight loss.
The surgical safety of bariatric surgery is an important consideration; many physicians and the general population in Korea appreciate that bariatric surgery is a risky procedure. In our study, the postoperative mortality rate was 0.38% (one case) and the immediate postoperative complication rate was 10%. The mortality rate in our study was comparable with that of a previous report in which the 30-day death rate among patients who underwent RYGB or LAGB was 0.3% [20] . However, the reported frequencies of adverse outcomes have varied and a direct comparison was not possible. In our study, the early postoperative complication rate of 10% and the rate of 13% after 30 days were considered to be acceptable because they included minor wound complications in the early period and long-term band-related complications in the late period.
This study had several limitations. First, although about 70% of bariatric surgeries in Korea are LAGBs performed in private clinics, this study included only those performed in tertiary hospitals. However, weight loss outcomes did not differ among surgical groups. Thus, although we did not include data from private clinics, the results seem to be generalizable. Second, our study was not randomized or prospective, but was designed as a retrospective cohort study. Thus, baseline characteristics differed between groups. The surgery group was younger, female dominant, higher BMI, and more comorbidities. This is because younger female patient usually want to receive surgery, and surgeons recommend bariatric surgery for patients who have higher BMI and comorbidities. To overcome this limitation, we used various statistical methods such as matching and the GEE model to balance confounding factors at baseline between the two groups. The results of these analyses were robust. Third, long-term outcomes and complications could not be examined because of the short follow-up period.
In conclusion, bariatric surgery had a significant effect on weight loss when compared with conventional medical therapy in severely obese Korean patients. The recovery from comorbidities such as diabetes, hypertension, and dyslipidemia was better in the surgery group than in the conventional therapy group. Our results suggest that bariatric surgery may be a favorable option for treating severe obesity in Koreans. Further studies are needed to elucidate the weight loss mechanisms of bariatric surgery, improvement in comorbid diseases, and long-term outcomes of bariatric surgeries in Korea.
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